Business
Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria
REDWOOD CITY, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of
About this update from Jasper Therapeutics, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that the first patient has been dosed in Jasper’s phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of CSU called BEACON (a phase 1b/2a Briquilimab dose Escalation trial assessing ACtivity, safety, and pharmacOkinetics iN adult patients with chronic spontaneous urticaria). The BEACON study is evaluating repeat doses of subcutaneous briquilimab in adult CSU patients who remain symptomatic after treatment with, or who cannot tolerate, omalizumab. “Dosing of the first patient in our BEACON study is an exciting milestone for Jasper as we advance the clinical development of briquilimab in mast cell diseases,” said Edwin Tucker, Chief Medical Officer of Jasper. “In addition to gathering safety data in CSU patients who are ineligible for, or refractory to, omalizumab, we expect the study to establish proof of concept for the depletion of mast cells by briquilimab in CSU. Results from the trial should also allow us to determine doses and dosing regimens for future registrational studies in the broader CSU patient population. We look forward to providing enrollment updates as we progress through the cohorts and anticipate reporting preliminary data in mid-2024.” The BEACON study is expected to enroll approximately 40 patients across 6 cohorts. The primary endpoints are safety and tolerability of briquilimab with secondary endpoints focused on efficacy measures and pharmacokinetics. The study is being conducted at sites in the US and EU. Jasper anticipates reporting preliminary data from the BEACON study in mid-2024. “We are pleased to announce that the first patient has been dosed in our BEACON study on a timeline consistent with our prior guidance,” said Ronald Martell, President and Chief Executive Officer of Jasper. “Treating the first patient so shortly after IND clearance is a testament to the hard work and diligence that Ed and his team put i...